医薬品の開発に
「実りある」
患者・市民参画を育てる
Multi-stakeholder Co-creation
Social co-creation with patients and public
Inclusive and sustainable participation from diverse backgrounds
Equitable and reciprocal benefits
Ongoing opportunities for mutual learning – not just receiving support or making requests
Concrete actions
Robust planning to return value to society
Clinical Trial Ambassador Project
Empirical research 'Using PED as Evidence'
A pilot case study 'Building PED using metaverse'
Patient-focused clinical trial ecosystem
Supporting citizen science
Interdisciplinary Approach to Science
Empirical research activities that foster patient and public involvement (PPI)
A Focus on Societal Implementation
Consultation to implement PPI
We offer consultations on PPI
in medicines development and clinical research.
Our team—representing various professional backgrounds—works with
companies, researchers, healthcare providers, and patient groups
to help put PPI into practice.
Participation in PFMD's initiative
Patient engagement and patient experience data
Patient engagement in health technology assessment
Global clinical trials ecosystem
Co-hosted by 1st PEOF+ Asia Pacific in Manila in 2026.
A Global Perspective
Systematizing PPI through international collaboration
News
2026.4.7
We have compiled a list of publicly accessible resources for learning about medicines development. Each resource is accompanied by information on its intended audience. This list was created as one of the outputs of the 2025 internship program.
-
List of Resources for Learning about Medicines Development (Japanese) ➡️
2026.4.7
We have compiled a list of publicly accessible resources for learning about medicines development. Each resource is accompanied by information on its intended audience. This list was created as one of the outputs of the 2025 internship program.
-
List of Resources for Learning about Medicines Development (Japanese) ➡️
2026.4.7
We have compiled a list of publicly accessible resources for learning about medicines development. Each resource is accompanied by information on its intended audience. This list was created as one of the outputs of the 2025 internship program.
-
List of Resources for Learning about Medicines Development (Japanese) ➡️
2026.3.31
The Ministry of Health, Labour and Welfare has issued "Regarding the Handling of Information Provision Related to Clinical Trials" (dated March 30, 2026, Pharmaceutical and Medical Affairs Bureau Notification No. 0330-1) and two related notices (➡️: Access to Ministry of Health, Labour and Welfare documents).
-
Regarding the handling of information provision related to clinical trials, etc. ➡️
-
Q&A regarding the handling of information provision related to clinical trials, etc. ➡️
-
Q&A regarding information provision by patient groups, etc., concerning clinical trials, etc. ➡️
2026.2.20
The proceedings of the 1st Roundtable on Patient Engagement and Patient Experience Data (PED) in Japan (we organised on October 18, 2025) have been published in Clinical Evaluation, Vol. 53, No. 3 .
-
English (original) ➡️
-
Japanese translation➡️
Public consultation
Public comment collection on new systems and guidelines regarding patient and citizen participation
We are currently soliciting public comments on the following new laws and systems. Anyone can submit their opinion.
If you have any questions, please contact us here: ✉ nobutaka.yagi@yoriailab.com
Events & Projects
Clinical Trial Ambassador Project
Highlights
New Resources ➡️
Meaningful Engagement
The discussion we presented at the Sequential Meetings - Consensus for Global Research Ethics and Meaningful Engagemen has been published in the December 2025 issue of Clinical Evaluation. YORIAILab endorses the Statement for Global REsearch Ethics Norm and Meaningful Engagement (GREEN Statement), which was adopted following a series of deliberations at the conference.
